To confirm this evidence, it has been recently reported that lower levels of baseline tumor adenosine are associated with a reduced efficacy of anti- PD-1/CTLA-4 mAbs in cohorts of ICI-treated patients (HR = 0.29, P = 0.00012) (78). Here, PDCD1 is linked to neoplasm.